You’re not going to tell me you read the last three days’ columns in their entirety – they were much too long, and much of that time the web site was down anyway. So go read ’em now. Especially the item about comparative oinkiness.
Today, let me just note that one of the firms that has been recommending Nitromed stock, Friedman, Billings, Ramsey & Co., yesterday reduced its forecasts for sales of BiDil, the company’s (only) product, from $17 million in 2005 to $7 million – 58% lower than previously. From $134 million in 2006 to $59.5 million – 55% lower. And from $232 million in 2007 to $134 million – 42% lower. And since sales are not all profit (the pills themselves cost almost nothing to produce, but there is a projected $120 million or so a year in other expenses), the reduction in expected profit in those years is presumably even steeper.
So by how much has this firm reduced its ‘target price’ for the stock, given that they think sales will be only half what they thought before? By 10%, from $32 to $29. (They now think 2008 will be the year big profits start to flow.)
NTMD closed at $16.32 last night, down from just over $22 when we first started talking about it July 6. Anything is possible, of course. But presuming you went into this with money you could truly afford to lose (as you still could): don’t sell your puts. Oink, oink.
Quote of the Day
Louis Pasteur's theory of germs is ridiculous fiction.~Pierre Pachet, Professor of Physiology at Toulouse, 1872
Request email delivery
- Jan 25:
What If? And Will He?
- Jan 23:
- Jan 22:
Talk About Crazy Coincidences!
- Jan 21:
Charlie Chaplin Speaks To Strongmen
- Jan 20:
China’s Greatest Strength Is America’s Greatest Weakness
- Jan 17:
Wishing You Good Health
- Jan 16:
Flip Trump Voters The Easy Way
- Jan 15:
A Crisis Of Despair
- Jan 14:
Progress Is Our Most Important Product
- Jan 13:
Benghazi, Uranium One, The Child Sex Ring . . .
- Jan 25: